-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Niu Xuejian, Deputy Director of the Shijiazhuang Municipal Administration for Market Regulation, visited Shijiazhuang Siyao to conduct a research visit on intellectual property work.
Category:
Time：2020-06-04
On June 2, Niu Xuejian, Deputy Director of the Shijiazhuang Municipal Administration for Market Regulation, led relevant staff from the Intellectual Property Utilization and Promotion Division to inspect the implementation status of the “High-Value Patent Portfolio Cultivation Project for Antiviral (Bacterial) and Antitumor Chemical Drugs” undertaken by Shijiazhuang Sihua Pharmaceutical. They also conducted a research visit and provided guidance on Shijiazhuang Sihua Pharmaceutical’s intellectual property work.
On June 2, Niu Xuejian, Deputy Director of the Shijiazhuang Municipal Administration for Market Regulation, led relevant staff from the Intellectual Property Utilization and Promotion Division to inspect the implementation status of the “High-Value Patent Portfolio Cultivation Project for Antiviral (Bacterial) and Antitumor Chemical Drugs” undertaken by Shijiazhuang Sihua Pharmaceutical. They also conducted a research visit and provided guidance on Shijiazhuang Sihua Pharmaceutical’s intellectual property work.
At the meeting, Wang Lijiang, Deputy Director of the Shijiazhuang No.4 Pharmaceutical Research Institute, delivered a detailed report on the company’s recent innovations in science and technology and intellectual property work, with a particular focus on the implementation status of the project aimed at developing high-value patent portfolios for antiviral (and antibacterial) and antitumor chemical drugs.
In recent years, Shijiazhuang No.4 Pharmaceutical has attached great importance to intellectual property management, establishing and improving its intellectual property management organization. It has continuously strengthened the responsibilities and authorities related to intellectual property application, protection, operation, and management. The company has developed a number of scientific and technological achievements with independent intellectual property rights and has successfully achieved their industrial application, thereby powerfully promoting technological advancement within the enterprise and providing robust innovation support for its transformation and development.
After listening to the report, Niu Xuejian praised Shijiazhuang No.4 Pharmaceutical’s practices and progress in intellectual property work, particularly the achievements it has made in patent licensing and patent transfer—key aspects of patent operations. He stated that innovation and intellectual property are fundamental guarantees for enterprise development, and intellectual property work is especially significant for the pharmaceutical industry. He encouraged enterprises to further enhance their awareness of intellectual property matters, strengthen their intellectual property systems, improve their capabilities in intellectual property protection and management, and leverage independent intellectual property rights to drive enterprise growth.
The research team also visited the Shijiazhuang No. 4 Pharmaceutical New Drug Research Institute, where they gained a detailed understanding of the institute’s R&D technologies, systems, and plans. They also received on-site answers to practical questions encountered in intellectual property practice.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license